ArticleBreast cancer research : BCR2010
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
Article in Breast cancer research : BCR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Quantifying pathway perturbations based on gene network rewiring in sepsis progression toward death or survival.Frontiers in bioinformatics · 2026Article
- Investigating the molecular mechanisms, drug prediction, and validation of CCNA2 and MAD2L1 in esophageal squamous cell carcinoma based on bioinformatics.BMC medical genomics · 2025Article
- Role and mechanism of IGFBP5 in the real-ambient particulate matter exposure-induced chronic lung injury.Frontiers in pharmacology · 2025Article
- Genetic co-expression networks contribute to creating predictive model and exploring novel biomarkers for the prognosis of breast cancer.Scientific reports · 2021Article
- BASP1 interacts with oestrogen receptor α and modifies the tamoxifen response.Cell death & disease · 2017Article
- A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.Scientific reports · 2017Article
- CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.Molecular medicine reports · 2016Article
- Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.Oncotarget · 2016Article
- Highly informative marker sets consisting of genes with low individual degree of differential expression.Scientific reports · 2015Article
- IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology.Journal of cell communication and signaling · 2015Article
- Article
- Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2.PloS one · 2015Article
- Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.British journal of cancer · 2014Article
- The tumor suppressor CDKN3 controls mitosis.The Journal of cell biology · 2013Article
- Detection of circulating tumour cells on mRNA levels with established breast cancer cell lines.Biomedical reports · 2013Article
- Identification of novel caspase/autophagy-related gene switch to cell fate decisions in breast cancers.Cell proliferation · 2013Article
- Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.PloS one · 2013Article
- Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay.Molecular & cellular proteomics : MCP · 2012Article
- Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Review
- Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers.Chinese journal of cancer · 2012Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
introductionTamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may well be expressed in a dynamic manner.
methodsIn this study we assessed gene expression changes at multiple time points (days 1, 2, 4, 7, 14) after tamoxifen treatment in the ER-positive ZR-75-1 xenograft model that displays significant changes in apoptosis, proliferation and angiogenesis within 2 days of therapy.
resultsHierarchical clustering identified six time-related gene expression patterns, which separated into three groups: two with early/transient responses, two with continuous/late responses and two with variable response patterns. The early/transient response represented reductions in many genes that are involved in cell cycle and proliferation (e.g. BUB1B, CCNA2, CDKN3, MKI67, UBE2C), whereas the continuous/late changed genes represented the more classical estrogen response genes (e.g. TFF1, TFF3, IGFBP5). Genes and the proteins they encode were confirmed to have similar temporal patterns of expression in vitro and in vivo and correlated with reduction in tumour volume in primary breast cancer. The profiles of genes that were most differentially expressed on days 2, 4 and 7 following treatment were able to predict prognosis, whereas those most changed on days 1 and 14 were not, in four tamoxifen treated datasets representing a total of 404 patients.
conclusionsBoth early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breast tumours in a dynamic manner. Temporal expression of therapy-response genes is clearly an important factor in characterising the response to endocrine therapy in breast tumours which has significant implications for the timing of biopsies in neoadjuvant biomarker studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.